Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted longer-term follow-up data from the Phase 3 trial of the COVID-19 mRNA vaccine in adolescents to the European Medicines Agency (EMA).
- The data from 2,228 individuals 12 through 15 years of age aims to support further the favorable safety and efficacy profile of Comirnaty in this age group.
- In the trial, a two-dose series of Comirnaty (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.
- Related: Pfizer Plans To Evaluate Third Shot For Its COVID-19 Vaccine In Kids Below 5 Years.
- Among 30 confirmed symptomatic cases of COVID-19 in the trial with and without evidence of prior infection with SARS-CoV-2 were in the placebo group, and no cases were in the Pfizer-BioNTech vaccine group.
- The adverse event profile was generally consistent with other clinical safety data for the vaccine. After the second dose, a favorable safety profile was observed in individuals with at least six months of safety follow-up.
- Price Action: PFE shares are down 1.94% at $58.40, and BNTX stock is down 0.85% at $257.50 during the market session on the last check Thursday.
- Photo by x3 from Pixabay
